Eribulin in Patients with Liposarcoma and Leiomyosarcoma: A Retrospective Single-Center Experience.

Abstract

INTRODUCTION:

Soft tissue sarcomas are rare and heterogenous malignancies with a poor prognosis in advanced disease stages. Eribulin is used in metastatic liposarcoma (LPS) patients, who have failed first-line chemotherapy and has been approved for use in patients with LPS in the USA and Europe due to its efficacy in this histological subtype in a phase 3 trial. We have evaluated efficacy and tolerability of eribulin in LPS and leiomyosarcoma (LMS) patients in the routine clinical setting at our department.

METHODS:

In this retrospective single-center analysis, efficacy and safety of eribulin were retrospectively evaluated in advanced LPS and LMS patients at the Division of Oncology, Medical University of Vienna.

RESULTS:

A total of 32 adult patients treated with eribulin were identified and included in this analysis. Overall response rate was 9.4% for all patients, with one patient with LPS and two patients with LMS showing a partial response. Disease control rate (partial response plus stable disease) for all patients was 50% (LPS: 47.1%; LMS 53.3%). No statistically significant difference in median progression-free survival and overall survival was detected between patients with LPS and LMS (p = 0.807 and p = 0.519, respectively). Patients with LMS (n = 2) had received fewer previous therapy lines than patients with LPS (n = 14) (≤ previous treatment lines, p < 0.001). Toxicity was generally manageable, and grade 3 + 4 events were rare.

CONCLUSION:

The activity and tolerability of eribulin in LPS as in well in LMS patients in the routine clinical setting is comparable to outcomes reported in published phase 3 trials.

• Authors: Oskar Steinbrecher, Thomas Brodowicz, Markus Raderer, Anke Scharrer, Johannes Fabsits, Wolfgang Lamm
• Journal: Oncology (Oncology) Vol. 101 Issue 2 Pg. 89-95 ( 2023) ISSN: 1423-0232 [Electronic] Switzerland
• PMID: 36273457 (Publication Type: Journal Article)
• Copyright: © 2022 The Author(s). Published by S. Karger AG, Basel.

Chemical References

• eribulin
• Lipopolysaccharides

Topics

• Adult
• Humans
• Leiomyosarcoma (drug therapy, pathology)
• Retrospective Studies
• Lipopolysaccharides (therapeutic use)
• Liposarcoma (drug therapy, pathology)